Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 863 Mitten Rd Ste 102 BURLINGAME CA 94010-1311 |
Tel: | 1-650-9004522 |
Website: | https://www.corvuspharma.com |
IR: | See website |
Key People | ||
Richard A. Miller Chairman of the Board, President, Chief Executive Officer | Leiv Lea Chief Financial Officer | William Benton Jones Senior Vice President - Pharmaceutical Development |
Business Overview |
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of ITK inhibition as a new approach to immunotherapy for a range of cancer and immune diseases. Its lead product candidate is soquelitinib, a selective, covalent inhibitor of ITK (interleukin 2 inducible T cell kinase) and is in a multi-center Phase 1/1b clinical trial in patients with various recurrent, malignant T cell lymphomas. Soquelitinib is designed to inhibit the proliferation of certain malignant T cells. Its second product candidate, ciforadenant, is an oral, small molecule antagonist of the A2A receptor for adenosine designed to disable a tumor's ability to subvert attack by the immune system by blocking the binding of immunosuppressive adenosine in the tumor microenvironment to the A2A receptor. The Company's third product candidate is mupadolimab, a humanized monoclonal antibody that is designed to react with a specific site on CD73. |
Financial Overview |
For the fiscal year ended 31 December 2023, Corvus Pharmaceuticals Inc revenues was not reported. Net loss decreased 35% to $27M. Lower net loss reflects Research and development - Balancing val decrease of 33% to $15.8M (expense), Loss from equity method investment decrease of 47% to $5.3M (expense), General and administrative - Balancing decrease of 15% to $5.5M (expense). |
Employees: | 28 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $60.14M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.00M as of Dec 31, 2023 |
EBITDA (TTM): | -$23.26M as of Dec 31, 2023 |
Net annual income (TTM): | -$27.03M as of Dec 31, 2023 |
Free cash flow (TTM): | -$23.97M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 49,038,582 as of Mar 19, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |